Licensing, Mergers & Acquisitions

Case Study

Bellus Health: BLUS

  • Geller Biopharm was retained to outlicense KIACTA, a Ph III asset for an orphan renal disorder
  • Initial work entailed
    • Positioning: focusing on orphan disease and creation of new markets
    • Presentation: building investor appropriate materials, and supporting marketing studies
  • Arranged introductions with 80+ US, EU and Asian pharmaceutical and biotech companies in the orphan, renal, and autoimmune space and brought management team to major US and EU conferences
  • Secured over 25 CDA's and led potential partners through online data rooms, onsite due diligence sessions and eventual term sheet negotiations with several companies
    • One of the largest pharmaceutical companies in the world remarked that Geller Biopharm had conducted the most thorough and well organized on-site diligence session their team has ever experienced
      • The testimonial may not be representative of the experience of other companies and is no guarantee of future performance or success
  • Brokered unique transaction in which Celtic Therapeutics paid an upfront fee to Bellus, covered all trial and filing costs to bring KIACTA to the market, with Bellus retaining 50% rights to the product
  • Past performance is not a guarantee of future results
Geller Biopharm

  Broker / Dealer services provided by Pickwick Capital Partners, LLC. Member FINRA / SIPC

Download our presentation
PDF

Get a digital copy of our PDF presentation

Download PDF